UCB Canda welcomes Jean-Christophe Tellier, global Chief Executive Officer and Chairman of the Executive Committee

On March 5, 2026, UCB Canada was delighted to welcome Jean-Christophe Tellier, Chief Executive Office and Chairman of the Executive Committee of UCB, to our Oakville offices. 
 

Coming together as one organization to deliver on UCB’s mission statement – inspired by patients, driven by science – this was a key strategic opportunity to celebrate the 3.1 million+ patients worldwide who accessed our innovative medicines and treatments in 2025 alone.
 

A passionate proponent of a humanistic approach to patient care and responsible for launching UCB’s Patient Value Strategy, Jean-Christophe’s personal experience as a clinical rheumatologist is a key driver of his and UCB’s global vision of improving patient care. Jean‑Christophe underscored the importance of evolving physician care and biopharmaceutical innovation to fully embrace a holistic understanding of each patient—their life, their experiences, and the environment that shapes their health. 
 

Bringing a special connection to Canada with a daughter having graduated McGill University, Jean-Christophe shared invaluable global market insights to support the UCB Canada team in bringing life-changing medicines to patients living with severe conditions in immunology, neurology, and rare diseases. 
 

Celebrating two decades of partnership and investment in Canada 

UCB Canada is proud to be celebrating 20 years of investment and dedication to Canadian patients. Currently experiencing a period of strong and rapid growth, UCB Canada is working with the Ontario Government and life sciences sector toward attracting sustainable investment, supporting innovation, and retaining local talent.

Learn more about UCB Canada’s growing footprint and multi-million-dollar expansion on Invest Ontario’s website. 

In 2025, UCB Canada was recognized as Belgian Company of the Year by the Belgian Canadian Business Chamber at the annual Business Excellence Awards, a true reflection of the Company’s ongoing commitment to the Canadian patients we serve. 

Strengthening the value of innovation in Canada 

During a time of tremendous geopolitical uncertainty, global economic upheaval, and significant health-system burden, it is critical that Canada finds new ways to remain competitive, attract investment, and support long-term innovation. 
To advance this goal of building Canada to be a true global leader, UCB convened a small group of leaders from industry, government, and the broader life science sector to discuss priority initiatives to accelerate equitable access to treatments for all Canadians. 
 

Jean-Christophe and Rodrigo Reis, General Manager, UCB Canada were joined by Tyler Allsopp, Parliamentary Assistant to the Minister of Economic Development, Job Creation and Trade; His Excellency Karl Anthony Amadeus Dhane, Ambassador of the Kingdom of Belgium to Canada; Luc Pirson, Counsellor, Embassy of Belgium in Canada; Bettina Hamelin, President, Innovative Medicines Canada; Jason Field, President and CEO, Life Sciences Ontario; Garrett Tone, Executive Director, Life Sciences, Defence, Aerospace, Invest Ontario; Paula Resende, Investment Lead, Life Sciences, Invest Ontario; and other key stakeholders for a collaborative discussion centred around practical steps to ensuring Canada maintains its commitment to a sustainable life sciences environment over the next five years.  
 

Recognizing we are stronger together, UCB Canada remains as dedicated as ever to improving the lives of Canadians with severe diseases through cutting-edge science and a steadfast commitment to patients and their families.